MaxSARBiopharma is a privately held, platform technology pharmaceutical company dedicated to overcoming compound liabilities so that they can progress into development.  MaxSAR will begin laboratory operations with equipment, supplies and start-up funding from an equity partner.  MaxSAR’s business model is to run collaboration projects for partners on an upfront payment and/or milestones and royalties basis as a way to self-fund internal project progression to Candidate, pre-IND, and POC, and to grow our platform. MaxSAR expects to support contract projects for two to three partners within the first year. 

MaxSAR’s proprietary technology is complementary to both traditional medicinal chemistry and combinatorial chemistry combining both biological and chemical transformations.  MaxSAR is able to identify improved compounds in three months and provide fully characterized improved compounds in six.  Our unique cross disciplinary team brings the latest high throughput technology to chemistry and uses a shot gun approach to chemically access, novel positions on pharmacologically active molecules to improve their druggability.

1. Validating Our Business Model
   Our currently business model is to self-fund based on profits from work done for partners. How do you think we should structure our fees/milestones/royalties for our first and future customers?  Are our expectations and budget realistic?
   Should we ask potential customers to invest at the same time?  Should we stay focused on pharmaceuticals or branch out to other industries early? 
   
   

2. Proprietary Projects
   Given the current FDA and payer environment, is it reasonable for us to expect to be able to sell a “me-better” at candidate, pre-IND or POC? 
   Where should we go to most efficiently find the best opportunities: physicians, thought leaders, meetings, consultants, pharmaceutical partnering websites?
   How should we pick internal projects for optimization? Big markets that pharma is very interested in or small niche markets that might be difficult to partner at Candidate, pre-IND or POC.    
   What is the best way for us to do preclinical trials: sell the compound at Candidate, find a partner to administer the studies, bring an expert in house to contract the work, set up a subsidiary to get funding for the work and execute it?  And where should we look for experts if we administer the work internally?
   
   

3. Lack of Track Record
   What can we reasonably show investors by way of POC to help them feel comfortable with the potential of our platform and our ability to execute? 

6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Dorothea Kominos – Head of Business Development, will deliver the Company's "Elevator" Pitch to the Group

8:20 - A Panel will address 3 Major Issues for the Company

9:00 - Open discussion: members and guests

<Top of the page>

Questions or Coments?

Contact: Dean M Martyniak

dean@rxpcci.com | (201) 390-1782